product name Riluzole
Description: Riluzole (also known as RP-54274, PK 26124) is a glutamate release inhibitor with neuroprotective, anticonvulsant, anxiolytic and anesthetic qualities. Riluzole acts by complex mechanism involving inhibition of voltage-dependent Na channels, high-voltage activated Ca and K channels, and inhibition of protein kinase C. It was suggested that this mechanism was involved in antioxidative processes.
References: Neurology. 1996 Dec;47(6 Suppl 4):S233-41; Naunyn-Schmiedebergs Archives of Pharmacology
234.2
Formula
C8H5F3N2OS
CAS No.
1744-22-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 47 mg/mL (200.7 mM)
Water: <1 mg/mL
Ethanol: 47 mg/mL (200.7 mM)
Solubility (In vivo)
Synonyms
RP-54274, PK 26124
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19423109
| In Vitro |
In vitro activity: Riluzole inhibits the release of glutamic acid from cultured neurons, and from brain slices. These effects may be partly due to inactivation of voltage-dependent sodium channels on glutamatergic nerve terminals, as well as activation of a G-protein-dependent signal transduction process. Electrophysiologic experiments performed on isolated excitatory amino acid receptors expressed in the Xenopus oocyte have revealed that Riluzole inhibits currents evoked by N-methyl-D-aspartate (NMDA) (IC50 = 18 μM) and kainic acid (IC50 = 167 μM). Riluzole has been shown to stabilize inactivated sodium channels in frog sciatic nerve, in rat cerebellar granule cells, and on recombinant rat sodium channels expressed in Xenopus oocytes (Ki = 0.2 μM). Riluzole also blocks some of the postsynaptic effects of glutamic acid by noncompetitive blockade of NMDA receptors. Tiluzole protects cultured neurons from anoxic damage, from the toxic effects of glutamic-acid-uptake inhibitors, and from the toxic factor in the CSF of patients with amyotrophic lateral sclerosis. Kinase Assay: Cell Assay: In HEKGLT1, HEKGLAST or HEKEAAC1 cells, riluzole increased Na+-dependent uptake in a dose-dependent manner, with significant effects at concentrations as low as 0.01–0.1 μM and the highest effect at 100 μM. The increase in glutamate uptake induced by 100 μM riluzole was similar in all cell lines (+27% in HEKGLAST, +38% in HEKGLT1, +39% in HEKEAAC1). Higher riluzole concentrations (300 and 1000 μM) were toxic, since at the end of experiments the majority of cells were floating, and specific and non-specific glutamate uptake were reduced by more than 50%. |
|---|---|
| In Vivo | Riluzole can easily cross the blood-brain barrier. Riluzole has neuroprotective, anticonvulsant, and sedative properties in vivo. In a rodent model of transient global cerebral ischemia, a complete suppression of the ischemia-evoked surge in glutamic acid release has been observed by Riluzole treatment (8 mg/kg i.p.). |
| Animal model | |
| Formulation & Dosage | |
| References | Neurology. 1996 Dec;47(6 Suppl 4):S233-41; Naunyn-Schmiedebergs Archives of Pharmacology |
